SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (8707)2/12/1999 10:53:00 PM
From: Robert K.  Read Replies (2) | Respond to of 17367
 
Oh I see, Robert S thinks we might administer oral products to the folks in endotoxic shock. It might save the HMO's some money.
Hey Robert S.> I dont see anyone screaming about oral epogen or oral neupogen. Perhaps we can just give them some ferrous sulfate instead. BTW> epo & Neupo> High cost injectables. Human orgin too I might add.
Actually in all seriousness RobertS has a valid issue, I just dont agree with it at all in this case.
I also see you all love that UK sight. Your welcome. VBG.
All IMO



To: Cacaito who wrote (8707)2/15/1999 7:22:00 PM
From: Robert S.  Read Replies (1) | Respond to of 17367
 
Cacaito...

Bpi will be very expensive and all insurances are going to pay for it.

In regard to your statement: while the former seems plausible, I have doubts pertaining to the latter.

Is this a fact or is this just your opinion?

Also, where is the evidence to support your assertions above?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News